Compounds > azacitidine

azacitidine and melphalan

azacitidine has been researched along with melphalan in 15 studies

Research

Studies (15)

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (13.33)	18.7374
1990's	2 (13.33)	18.2507
2000's	4 (26.67)	29.6817
2010's	6 (40.00)	24.3611
2020's	1 (6.67)	2.80

Authors

Authors	Studies
Hansch, C; Khwaja, TA; Selassie, CD	1
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J	1
Lombardo, F; Obach, RS; Waters, NJ	1
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Bigner, DD; Friedman, HS; Schold, SC	1
Hall, EJ; Miller, RC; Osmak, R; Zimmerman, M	1
Adams, EG; Bhuyan, BK; Folz, BA; Smith, KS	1
Connolly, DC; Dinulescu, DM; Donahoe, PK; Halpern, EF; MacLaughlin, DT; Pearsall, LA; Pieretti-Vanmarcke, R; Seiden, MV	1
Andersson, BS; Champlin, RE; Li, Y; Murray, D; Nieto, Y; Valdez, BC; Wang, G	1
Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Bashir, Q; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hosing, C; Jones, RB; Myers, A; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shah, N; Shpall, EJ; Thall, PF; Valdez, BC; Wei, W	1
Amiot, M; Chiron, D; Descamps, G; Djamai, H; Gillardin, PS; Le Gouill, S; Lucani, B; Maiga, S; Moreau, P; Moreau-Aubry, A; Pellat-Deceunynck, C; Tessoulin, B	1
Anaclerico, B; Andriani, A; Aroldi, A; Breccia, M; Carmosino, I; Centra, A; Di Veroli, A; Elli, E; Fianchi, L; Foà, R; Latagliata, R; Martini, V; Montanaro, G; Montanaro, M; Niscola, P; Trapè, G; Villivà, N; Voso, MT	1
Ishiguro, C; Kawashiri, A; Kurokawa, T; Maeda, Y; Mochizuki, K; Nakagawa, SI	1

Reviews

1 review(s) available for azacitidine and melphalan

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Other Studies

14 other study(ies) available for azacitidine and melphalan

Article	Year
Structure-activity relationships of antineoplastic agents in multidrug resistance. Journal of medicinal chemistry, 1990, Volume: 33, Issue:7 Topics: Animals; Antineoplastic Agents; Cell Line; Cell Survival; Cricetinae; Dactinomycin; Drug Resistance; Leukemia L1210; Mice; Regression Analysis; Structure-Activity Relationship; Tumor Cells, Cultured	1990
Chemical genetics reveals a complex functional ground state of neural stem cells. Nature chemical biology, 2007, Volume: 3, Issue:5 Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells	2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. Journal of medicinal chemistry, 2008, Nov-13, Volume: 51, Issue:21 Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship	2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Chemotherapy of subcutaneous and intracranial human medulloblastoma xenografts in athymic nude mice. Cancer research, 1986, Volume: 46, Issue:1 Topics: Animals; Azacitidine; Brain Neoplasms; Cell Line; Cytarabine; Doxorubicin; Humans; Medulloblastoma; Melphalan; Mice; Mice, Nude; Mitoguazone; Neoplasm Transplantation; Nitrosourea Compounds; Skin Neoplasms; Vidarabine Phosphate	1986
Comparison of the incidence of oncogenic transformation produced by X rays, misonidazole, and chemotherapy agents. Radiology, 1982, Volume: 145, Issue:2 Topics: Animals; Antineoplastic Agents; Azacitidine; Cell Survival; Cell Transformation, Neoplastic; Cells, Cultured; Cisplatin; Doxorubicin; Fibroblasts; In Vitro Techniques; Melphalan; Mice; Misonidazole; Nitroimidazoles; Radiation, Ionizing; Vincristine; X-Rays	1982
Synergistic and additive combinations of several antitumor drugs and other agents with the potent alkylating agent adozelesin. Cancer chemotherapy and pharmacology, 1995, Volume: 35, Issue:6 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aphidicolin; Azacitidine; Benzofurans; Caffeine; Cell Survival; CHO Cells; Cisplatin; Cricetinae; Cricetulus; Cyclohexanecarboxylic Acids; Cyclohexenes; Decitabine; Deoxyadenosines; DNA; Dose-Response Relationship, Drug; Drug Synergism; Duocarmycins; Indoles; Melanoma, Experimental; Melphalan; Mutagens; Organoplatinum Compounds; Pentoxifylline; Tumor Cells, Cultured	1995
Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2006, Nov-14, Volume: 103, Issue:46 Topics: Animals; Anti-Mullerian Hormone; Apoptosis; Azacitidine; Cell Line, Tumor; Decitabine; Drug Resistance, Neoplasm; Female; Glycoproteins; Humans; Immunoglobulin G; Melphalan; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Receptors, Peptide; Receptors, Transforming Growth Factor beta; Testicular Hormones; Xenograft Model Antitumor Assays	2006
Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines. Experimental hematology, 2012, Volume: 40, Issue:10 Topics: Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Azacitidine; Busulfan; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 2; Cytotoxins; Decitabine; Deoxycytidine; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; DNA Methyltransferase 3B; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Epigenesis, Genetic; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Hydroxamic Acids; Lymphoma; Melphalan; Protein Serine-Threonine Kinases; Transplantation Conditioning; Transplantation, Homologous; Tumor Suppressor Proteins	2012
Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. Cancer, 2016, 09-01, Volume: 122, Issue:17 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Busulfan; Child; Deoxycytidine; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Follow-Up Studies; Gemcitabine; Humans; Hydroxamic Acids; Lymphoma; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Vorinostat; Young Adult	2016
Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells. International journal of molecular sciences, 2017, Dec-23, Volume: 19, Issue:1 Topics: Azacitidine; Base Sequence; Cell Line, Tumor; Cisplatin; CpG Islands; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Melphalan; Multiple Myeloma; Tumor Protein p73; Tumor Suppressor Protein p53	2017
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors. Hematological oncology, 2019, Volume: 37, Issue:3 Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Female; Humans; Hydroxyurea; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Melphalan; Middle Aged; Mutation; Myeloproliferative Disorders; Pipobroman; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Remission Induction; Retrospective Studies; Thrombocythemia, Essential; Treatment Outcome	2019
Donor-derived diffuse large B-cell lymphoma after haploidentical stem cell transplantation for acute myeloid leukemia. Journal of clinical and experimental hematopathology : JCEH, 2022, Volume: 62, Issue:3 Topics: Antilymphocyte Serum; Azacitidine; Busulfan; Epstein-Barr Virus Infections; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Herpesvirus 4, Human; HLA Antigens; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Methotrexate; Middle Aged; Positron Emission Tomography Computed Tomography; Tacrolimus; Transplantation Conditioning	2022